Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Diabetic Retinopathy in T2DM
NCT05310916Phase 3Unknown
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in diabetic retinopathy (DR) (2 arms). Primary endpoints: Severity of retinopathy at 12 weeks, Evaluation of the study biomarkers, IL-6 at 12 weeks and 1 more. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05310916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310916.